Atazanavir Sulfate

NDC 0093-5527 · Teva Pharmaceuticals USA, Inc.

Generic nameAtazanavir Sulfate

Dosage formCAPSULE

RouteORAL

Active ingredient(s)ATAZANAVIR SULFATE

Strength200 mg/1

Pharmacologic classCytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inhibitors [MoA], UGT1A1 Inhibitors [MoA]

Marketing categoryANDA

Packages

0093-5527-06 — 60 CAPSULE in 1 BOTTLE (0093-5527-06)

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

0003-3622 — ATAZANAVIR, 0003-3631 — ATAZANAVIR, 0003-3638 — ATAZANAVIR, 0003-3641 — atazanavir and cobicistat, 0093-5526 — Atazanavir Sulfate, 0093-5528 — Atazanavir Sulfate, 31722-653 — Atazanavir, 31722-654 — Atazanavir, 31722-655 — Atazanavir, 42385-920 — Atazanavir, 42385-921 — Atazanavir, 42385-922 — Atazanavir, 65862-710 — Atazanavir, 65862-711 — Atazanavir, 65862-712 — Atazanavir, 65862-713 — Atazanavir

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release). All data sources · How to read the labels